Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pharmacogenetic test possibility for beta-blocker therapy:

This article was originally published in Clinica

Executive Summary

Researchers have moved closer to developing a pharmacogenetic test to determine which patients with acute coronary syndrome (ACS) are suitable for beta-blocker therapy, according to findings published in the Journal of the American Medical Association (September 28). Patients with certain gene variants who were prescribed beta-blocker drugs after acute coronary syndrome ACS had an increased risk of death over the next three years, the investigators report. DNA testing on 597 ACS patients who were discharged from hospital with beta-blocker therapy was conducted to find out if the patients carried any of four common variants of the ADRB1 and ADRB2 genes, previously reported to be linked to beta-blocker therapy. A significant association was found between the ADRB2 genotype and three-year mortality among patients prescribed beta-blocker therapy.

You may also be interested in...



Celltrion Invests $450m Into Incheon Manufacturing Site

Celltrion has announced plans to add a third biopharmaceutical facility and a new global biotechnology research center at the Korean firm’s existing site in Songdo, Incheon, as the firm also revealed record third-quarter financial results.

Jefferies' Survey Predicts M&A Rebound In 2021

An upturn in M&A activity across the whole healthcare sector is expected in 2021, with the COVID-19 pandemic and the associated development of a vaccine shining a light on the sector, says a recent survey by Jefferies. 

Clinuvel’s Phototoxicity Drug Scenesse Approved In Third Market

Australian patients with phototoxicity due to the rare condition EPP will now have their first treatment option – provided the drug's developer, Clinuvel, secures reimbursement under the Pharmaceutical Benefits Scheme.

Topics

UsernamePublicRestriction

Register

OM014142

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel